Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling by array of low- and high-grade resected tumors from glioma patients

ABSTRACT: Samples of resected tumor from patients with low- and high-grade gliomas

ORGANISM(S): Homo sapiens

SUBMITTER: Mieczkowski Jakub

PROVIDER: S-ECPF-MTAB-1928 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of 20 human primary high grade glioma cell cultures

Project description:Gene expression profiling of 20 primary high grade glioma cell cultures

| S-ECPF-MEXP-1063 | biostudies-other

IDH1-R132H Low Grade Glioma animal brain tumors

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-03-18 | GSE94976 | GEO

RNA seq of mouse low grade glioma tumors

Project description:RNA sequencing was performed on paraffin embedded mouse low grade glioma tumor tissue

2022-09-12 | GSE172391 | GEO

Transcription profiling by array of human pancreatic tumors

Project description:We used microarrays to identify the expression differences of FKBP5 gene between the pancreatic tumor and normal samples. On average normal samples had more FKBP5 expression compared to tumor samples .Experiment Overall Design: This experiment consists of 36 tumor samples and 16 normal samples; a total of 52 samples. 16 samples consist of both tumor and normal expression data, whereas 20 samples consist of only tumor data.

| S-ECPF-GEOD-16515 | biostudies-other

Transcription profiling of high and low grade gliomas from human patients to identify new diagnostic and prognostic markers

Project description:Comparison of high grade to low grade gliomas.

| S-ECPF-TABM-167 | biostudies-other

Transcription profiling of human grade II astrocytic tumor (astrocytomas) vs grade IV tumors (glioblastoma)

Project description:Comparison of grade II astrocytic tumor (astrocytomas) with grade IV tumors (glioblastoma)

| S-ECPF-MEXP-567 | biostudies-other

Proteomic Profiling of mouse High Grade Glioma

Project description:High throughput proteomics profiling provide an unprecedented opportunity for dissecting molecular mechanisms in cancer biology. Here we present deep profiling of whole proteome and phosphoproteome in two high-grade glioma mouse models driven by mutated receptor tyrosine kinase (RTK) oncogenes. Using multiplex isobaric labeling (10-plex TMT) coupled with extensive liquid chromatography and mass spectrometry, we analyzed ~ 12K genes and > 30K phosphosites by extensive mass spectrometry. Systematical reprogramming of the proteome and phosphoproteome were observed in HGG tumors compare to normal cortex.

2019-06-24 | PXD005360 | Pride

Low-grade glioma microglia

Project description:To examine the effect of Nf1 inactivation in astrocytes on normal microglia in the optic nerve, microglia from Nf1 flox/flox (FF) and Nf1 flox/flox; GFAP-Cre (FFC) were flow sorted. High throughput RNA-seq was employed to compare the expression profiles, and upregulated genes in microglia supportive to Nf1 deficient astrocytes were verified.

2020-07-03 | GSE65865 | GEO

Thromboembolic disease in patients with high-grade glioma.

Project description:Venous thromboembolism (VTE) is common throughout the course of disease in high-grade glioma (HGG). The interactions between the coagulation cascade, endothelium, and regulation of angiogenesis are complex and drive glioblastoma growth and invasion. We reviewed the incidence of VTE in HGG, the biology of the coagulome as related to glioblastoma progression, prevention and treatment of thrombosis, and the putative role of anticoagulants as anti-cancer therapy. VTE can be significantly reduced during the postoperative period with adherence to the use of mechanical and medical thromboprophylaxis. Activation of the coagulation cascade occurs throughout the course of disease because of a variety of complex interactions, including tumor hypoxia, upregulation of VEGR expression, and increases in both tumor cell-specific tissue factor (TF) expression and inducible TF expression in numerous intrinsic regulatory pathways. Long-term anticoagulation to prevent VTE is an attractive therapy; however, the therapeutic window is narrow and current data do not support its routine use. Most patients with proven symptomatic VTE can be safely anticoagulated, including those receiving anti-VEGF therapy, such as bevacizumab. Initial therapy should include low molecular weight heparin (LMWH), and protracted anticoagulant treatment, perhaps indefinitely, is indicated for patients with HGG because of the ongoing risk of thrombosis. A variety of coagulation- and tumor-related proteins, such as TF and circulating microparticles, may serve as potential disease-specific biomarkers in relation to disease recurrence, monitoring of therapy, and as potential therapeutic targets.

| S-EPMC3480243 | biostudies-literature

Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures.

Project description:ObjectiveHere, we retrospectively investigate the value of voxel-wisely plotted diffusion tensor-derived (DTI) axial, radial and mean diffusivity for the early detection of malignant transformation (MT) in WHO II glioma compared to contrast-enhanced images.Materials and methodsForty-seven patients underwent brain magnetic resonance imaging follow-up between 2006-2014 after gross-tumor resection of intra-axial WHO II glioma. Axial/Mean/Radial diffusivity maps (AD/MD/RD) were generated from DTI data. ADmin/MDmin/RDmin values were quantified within tumor regions-of-interest generated by two independent readers including tumor contrast-to-noise (CNR). Sensitivity/specificity and area-under-the-curve (AUC) were calculated using receiver-operating-characteristic analysis. Inter-reader agreement was assessed (Cohen's kappa).ResultsEighteen patients demonstrated malignant transformation (MT) confirmed in 8/18 by histopathology and in 10/18 through imaging follow-up. Twelve of 18 patients (66.6%) with MT showed diffusion restriction timely coincidental with contrast-enhancement (CE). In the remaining six patients (33.3%), the diffusion restriction preceded the CE. The mean gain in detection time using DTI was (0.8±0.5 years, p = 0.028). Compared to MDmin and RDmin, ROC-analysis showed best diagnostic value for ADmin (sensitivity/specificity 94.94%/89.7%, AUC 0.96; p<0.0001) to detect MT. CNR was highest for AD (1.83±0.14), compared to MD (1.31±0.19; p<0.003) and RD (0.90±0.23; p<0.0001). Cohen's Kappa was 0.77 for ADmin, 0.71 for MDmin and 0.65 for RDmin (p<0.0001, respectively).ConclusionMT is detectable at the same time point or earlier compared to T1w-CE by diffusion restriction in diffusion-tensor-derived maps. AD demonstrated highest sensitivity/specificity/tumor-contrast compared to radial or mean diffusivity (= apparent diffusion coefficient) to detect MT.

| S-EPMC5065360 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data